Primary targets of fluoroquinolones in Streptococcus pneumoniae

被引：144

作者：

Fukuda, H

Hiramatsu, K

机构：

[1] Kyorin Pharmaceut Co Ltd, Cent Res Labs, Shimotsuga, Tochigi 3290114, Japan

[2] Juntendo Univ, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 02期

关键词：

D O I：

10.1128/AAC.43.2.410

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Mutants of wild-type Streptococcus pneumoniae IID553 with mutations in parC were obtained by selection with trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin. All of the parC mutants were cross-resistant to the selecting agents but were not resistant to gatifloxacin and sparfloxacin. On the other hand, gyrA mutants were isolated by selection with gatifloxacin and sparfloxacin. The gyrA mutants were cross-resistant to gatifloxacin and sparfloxacin but were not resistant to the other fluoroquinolones tested. These results suggest that in wild-type S. pneumoniae the primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin is topoisomerase IV, whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase.

引用

收藏

页码：410 / 412

页数：3

相关论文

共 21 条

[11] Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus [J].

Ng, EY ;

Trucksis, M ;

Hooper, DC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1881-1888

[12] Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones [J].

Pan, XS ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :471-474

[13] Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance [J].

Pan, XS ;

Fisher, LM .

JOURNAL OF BACTERIOLOGY, 1996, 178 (14) :4060-4069

[14] Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].

Pan, XS ;

Ambler, J ;

Mehtar, S ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326

[15] Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae [J].

Perichon, B ;

Tankovic, J ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1166-1167

[16] Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae [J].

Piddock, LJV ;

Jin, YF ;

Everett, MJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (05) :609-615

[17] Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro [J].

Tankovic, J ;

Perichon, B ;

Duval, J ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2505-2510

[18] Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus [J].

Yamagishi, JI ;

Kojima, T ;

Oyamada, Y ;

Fujimoto, K ;

Hattori, H ;

Nakamura, S ;

Inoue, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1157-1163

[19] QUINOLONE RESISTANCE-DETERMINING REGION IN THE DNA GYRASE GYRA GENE OF ESCHERICHIA-COLI [J].

YOSHIDA, H ;

BOGAKI, M ;

NAKAMURA, M ;

NAKAMURA, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1271-1272

[20] QUINOLONE RESISTANCE-DETERMINING REGION IN THE DNA GYRASE GYRB GENE OF ESCHERICHIA-COLI [J].

YOSHIDA, H ;

BOGAKI, M ;

NAKAMURA, M ;

YAMANAKA, LM ;

NAKAMURA, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1647-1650